Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis

Tijn M. S. van Winden1,2, Tobias A. J. Nijman3, C. Emily Kleinrouweler1,2, Raed Salim4, Maryam Kashanian5, Wafa R. Al-Omari6, Eva Pajkrt1,2, Ben W. Mol7, Martijn A. Oudijk2,8,9* and Carolien Roos2,8

Abstract

Background: Worldwide, nifedipine and atosiban are the two most commonly used tocolytic agents for the treatment of threatened preterm birth. The aim of this study was to evaluate the effectiveness of nifedipine and atosiban in an individual participant data meta-analysis (IPDMA).

Methods: We investigated the occurrence of adverse neonatal outcomes in women with threatened preterm birth by performing an IPDMA, and sought to identify possible subgroups in which one treatment may be preferred. We searched PubMed, Embase, and Cochrane for trials comparing nifedipine and atosiban for treatment of threatened preterm birth between 240/7 and 340/7 weeks’ gestational age. Primary outcome was a composite of perinatal mortality and neonatal morbidities including respiratory distress syndrome, intraventricular haemorrhage, periventricular leucomalacia, necrotising enterocolitis, and sepsis. Secondary outcomes included NICU admission, prolongation of pregnancy and GA at delivery. For studies that did not have the original databases available, metadata was used. This led to a two-stage meta-analysis that combined individual participant data with aggregate metadata.

Results: We detected four studies (N = 791 women), of which two provided individual participant data (N = 650 women). The composite neonatal outcome occurred in 58/364 (16%) after nifedipine versus 69/359 (19%) after atosiban (OR 0.76, 95%CI 0.47–1.23). Perinatal death occurred in 14/392 (3.6%) after nifedipine versus 7/380 (1.8%) after atosiban (OR 2.0, 95%CI 0.80–5.1).

Nifedipine results in longer prolongation of pregnancy, with a 18 days to delivery compared with 10 days for atosiban (HR 0.83 (95%CI 0.69–0.99)). NICU admission occurred less often after nifedipine (46%) than after atosiban (59%), (OR 0.32, 95%CI 0.14–0.75). The sensitivity analysis revealed no difference in prolongation of pregnancy for 48 hours (OR 1.0, 95% CI 0.73–1.4) or 7 days (OR 1.3, 95% CI 0.85–5.8) between nifedipine and atosiban. There was a non-significant higher neonatal mortality in the nifedipine-exposed group (OR 1.4, 95% CI 0.60–3.4).

Conclusions: In this IPDMA, we found no differences in composite outcome between nifedipine and atosiban in the treatment of threatened preterm birth. However, the non-significant higher mortality after administering nifedipine warrants further investigation of the use of nifedipine as a tocolytic drug.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Tweetable abstract
IPDMA of two RCTs comparing tocolytics nifedipine and atosiban as treatment of threatened preterm birth. Baby outcomes were similar. Although mortality was higher with nifedipine, this difference could have occurred by chance.

Key message
In this comparison between nifedipine and atosiban, no drug is clearly superior to the other. Nifedipine is associated with a prolongation of pregnancy. However, this does not yield better neonatal outcomes.

Background
Preterm birth is one of the biggest challenges in obstetrics, responsible for an estimated 1.12 million neonatal deaths per year [1, 2]. Preterm birth is the largest cause of neonatal death and the second leading cause of deaths among children under the age of 5 years, making it one of the main direct causes of infant mortality [3].

An important intervention to improve neonatal outcome is administration of antenatal corticosteroids to enhance fetal lung maturation in case of threatened preterm birth. Antenatal corticosteroids require 48 hours to reach the maximum effect. Because of this, many protocols have incorporated administration of tocolytic drugs to delay birth for 48 hours [4]. When applicable to the local situation, in utero transfer to a tertiary center is crucial.

In the past decades, various tocolytic agents have been investigated and made available for clinical use [4]. Currently, the two most commonly used tocolytic drugs are atosiban, an oxytocin receptor antagonist, and nifedipine, a calcium channel blocking agent. However, there is no consensus on which drug is the optimal drug to use in clinical practice, also regarding safety. The heterogeneity in treatment strategies and outcome measures have made it difficult to interpret study outcomes in a clinical setting. We believe that perinatal outcome should be the main treatment goal, more important than prolongation of pregnancy. With this study, we aim to address this knowledge gap. Moreover, in specific subsets of women with threatened preterm birth, such as with ruptured membranes versus intact membranes the optimal drug might differ from the general population with threatened preterm birth.

Methods
Aim
To systematically assess the question which is the optimal tocolytic agent to administer, we performed an individual participant data meta-analysis (IPDMA) in which we compared nifedipine with atosiban with respect to neonatal outcome in women with threatened preterm birth and multiple subgroups.

Trial registration
This IPDMA was conducted according to a prospectively prepared protocol, registered with PROSPERO (the International Prospective Register of Systematic Reviews) under CRD42016024244. We followed the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) guidelines for the meta-analysis of randomized controlled trials [5].

Sources and search strategy
We searched PubMed, Embase and Cochrane databases for trials that compared tocolysis with nifedipine and atosiban in threatened preterm birth. We used the keywords and synonyms of “nifedipine” AND “atosiban” AND “preterm birth”. Furthermore, we searched clinicaltrials.gov and isrctn.com for continuing or unpublished studies. The last search was conducted on 13 April 2022. The search strategy is presented in appendix S1.

Eligibility criteria and study selection
Studies were eligible for inclusion in this IPDMA if they were a randomized controlled trial comparing nifedipine with atosiban for 48 hours of tocolysis in women with threatened preterm birth between 240/7 and 340/7 weeks of gestation. Corresponding authors of eligible studies were contacted and invited to participate in the IPDMA. Authors who replied positively were provided with a detailed project protocol and they were asked to send their original, anonymized data. Additional information was extracted from the original papers. Shared data were reformatted or recoded if necessary to acquire uniformity, and merged into one database.

Outcomes
The primary outcome was a composite of neonatal morbidities and perinatal mortality, according to the...
registered study protocol, where available. Neonatal morbidities included bronchopulmonary dysplasia (BPD), periventricular leukomalacia (PVL) ≥ stage II, intraventricular hemorrhage (IVH) ≥ grade III, necrotizing enterocolitis (NEC) ≥ stage II and culture proven sepsis.

Secondary outcomes were time to delivery, gestational age at delivery, successful 48 hours of tocolysis, maternal side effects, blood loss during delivery and days on ventilation support.

As not all planned outcome measures were available in the shared datasets, our composite outcome was as follows: respiratory distress syndrome (RDS, requiring surfactant), periventricular leukomalacia (PVL) ≥ stage II, intraventricular hemorrhage (IVH) ≥ grade III, necrotizing enterocolitis (NEC) ≥ stage II and culture proven sepsis.

Additional available outcomes where: NICU admission, ventilation support, total days in hospital, total days in hospital until corrected age 3 months, apnea and birthweight.

**Statistical analyses**

Data on baseline characteristics and outcomes were summarized for the complete database and for the two study groups within each study. Continuous variables were presented as means with standard deviations (SD) or as medians with interquartile ranges (IQR), as appropriate. Dichotomous or categorical variables were presented as the number and percentage of the study-specific or total study population. Outcomes were analyzed by an intention-to-treat approach. For binomial outcomes, we used a mixed model with a log link, thus resulting in odds ratios (OR) with 95% confidence intervals (95% CI). These models include a random intercept to account for differences in prevalence between studies and to control for between-study heterogeneity [6]. Gestational age at delivery and time to delivery were analyzed with Cox proportional hazard models, stratified at the study level, and Kaplan-Meier estimates and tested with a log-rank test. We censored gestational age at delivery at 37+0 weeks of gestation as we were mainly interested in the effect of tocolytic therapy on prolonging pregnancy in the preterm period.

For outcomes on child level, we accounted for interdependence between outcomes of babies of the same mother in multiple pregnancies [7]. We assessed binary outcomes with a generalized estimating equations (GEE) model for binomial data with an unstructured correlation matrix, considering the mother as a cluster variable. Odds ratios with 95% CI and P values are reported. Likewise, we evaluated continuous outcomes on the child level with linear quantile mixed models with the mother as a grouping variable, resulting in a median difference with 95% CI [8].

The presence of statistical heterogeneity of outcomes across studies was assessed using the I² measure and interpreted as follows: 0% indicated no observed heterogeneity; 25, 50, and 75% indicate low, moderate, and high heterogeneity, respectively [9].

Data preparation and statistical analyses were performed using SPSS (version 25.0, IBM Corp, Armonk, NY, USA) and R (version 3.5.1, R Core Team, Vienna, Austria).

**Risk of bias assessment**

Two review authors independently assessed the risk of bias of each included study against key criteria: random sequence generation; allocation concealment; blinding of participants, personnel and outcomes; incomplete outcome data; selective outcome reporting; and other sources of bias, in accordance with methods recommended by The Cochrane Collaboration [10]. The following judgements were used: low risk, high risk, or unclear (either lack of information or uncertainty over the potential for bias). Authors resolved disagreements by consensus, and a third author was consulted to resolve disagreements if necessary.

**Subgroup analysis**

We investigated possible subgroup effects for women with ruptured and intact membranes, gestational age at randomization <30° versus ≥30° weeks, cervical dilation at randomization <2 versus ≥2 cm, singleton and multiple pregnancies, nulliparous and parous women, women with and without a history of preterm birth, women with and without a history of term birth, and neonatal sex (boys versus girls).

Subgroup effects were studied by including an interaction term between the subgrouping variable and treatment allocation in the regression model. When the interaction term was found to be significant (P<0.10), we performed a stratified analysis in different strata of the subgroups. Subgroup analyses were only performed for gestational age at delivery, time to delivery, successful 48 hours of tocolysis, composite adverse neonatal outcome and ventilation support.

**Sensitivity analysis**

To aggregate all possible evidence, including studies not providing individual participant data, we performed a sensitivity analysis. We combined individual participant data when available, and aggregate metadata for studies who did not provide individual patient data in a two-stage meta-analysis.
Results

Study selection

The literature search resulted in 176 citations, showing 4 trials that were eligible for inclusion, Van Vliet et al., Lancet 2016; Salim et al., Obstet Gynecol 2012; Al-Omari et al., Eur J Obstet Gynecol Reprod Biol 2006; Kashanian et al., Int J Gynecol Obstet 2005 [11–14]. A search on clinicaltrials.gov and isrctn.com resulted in no additional suitable trials. Details on study selection and the search strategy are specified in Appendix S1.

All four corresponding authors were interested in collaboration. From two studies (Al-Omari et al. and Kashanian et al.), individual participant data could not be provided because it was reported that the original database was lost [13, 14]. Thus, from the four studies reporting on 791 women, we could use individual participant data of the two largest studies (n = 650 women). The original databases were used to construct the IPDMA data set. As the shared datasets had either (almost) complete data for all variables or additional variables were not recorded at all, we did not impute missing data. Additional investigation based on all studies’ metadata was conducted as sensitivity analysis.

Study characteristics

Sample sizes of the studies were 505 and 145 women; 324 women were treated with nifedipine and 326 women with atosiban as tocolytic therapy. All studies evaluated nifedipine treatment against atosiban treatment [11–14].

Results of IPDMA (synthesis of two largest studies)

Table 1 shows the baseline characteristics of the nifedipine and atosiban groups for all included women and in the two separate trials. Most characteristics were distributed evenly, indicating no clinical difference between the nifedipine and atosiban group. There were slightly more multiples in the nifedipine group (22.3%) than in the atosiban group (18.1%).

Women included in Van Vliet et al. were slightly older, had a higher BMI and lower gestational age at randomization, compared to Salim et al. In Salim’s population, more women had a twin pregnancy and more women experienced previous preterm birth.

The composite outcome did not differ significantly between the nifedipine and the atosiban group (15.9% versus 19.2% respectively, OR 0.76, 95% CI 0.47–1.23). Similarly, there was no significant difference in perinatal death (3.6% versus 1.8%, OR 2.01, 95% CI 0.80–5.06). All components of the primary outcome are listed in Table 2 and secondary outcomes in Table 3.

Table 1 Baseline characteristics

| Characteristics                  | IPDMA Nifedipine (n = 324) | Atosiban (n = 326) | Van Vliet Nifedipine (n = 249) | Atosiban (n = 256) | Salim Nifedipine (n = 75) | Atosiban (n = 70) |
|----------------------------------|-----------------------------|-------------------|-------------------------------|-------------------|--------------------------|-------------------|
| Age (years)                      | 30.1 (26.0–34.0)            | 30.0 (26.6–33.0)  | 30.7 (26.2–34.1)              | 30.2 (27.1–33.1)  | 27.0 (25.0–33.0)          | 28.0 (25.0–32.3)  |
| BMI (kg/m²)                      | 22.7 (20.4–25.6)            | 22.8 (20.4–25.5)  | 23.1 (20.8–25.8)              | 22.8 (20.5–25.6)  | 21.4 (19.9–25.0)          | 22.6 (20.2–25.3)  |
| Nulliparous                       | 197/323 (61)                | 195/325 (60)      | 160/248 (65)                  | 170/255 (67)      | 37 (49)                   | 25 (36)           |
| Multiple pregnancy               |                             |                   |                               |                   |                          |                   |
| - Twin                           | 72 (22)                     | 58 (18)           | 49 (20)                       | 37 (15)           | 23 (31)                   | 21 (30)           |
| - Triplet                        | 0                           | 1 (0.3)           | 0                             | 1 (0.4)           | 0                        | 0                 |
| Previous preterm birth           | 45/323 (14)                 | 45/324 (14)       | 33/248 (13)                   | 30/254 (12)       | 12 (16)                   | 15 (21)           |
| Gestational age at study entry (weeks) | 31.1 (29.0–33.0)       | 30.8 (28.9–32.6)  | 30.9 (28.7–32.9)              | 30.7 (28.6–32.4)  | 31.9 (30.0–33.1)          | 31.1 (29.7–32.8)  |
| PPROM at study entry             | 85 (26)                     | 88 (27)           | 85 (34)                       | 88 (34)           | 0                        | 0                 |
| Vaginal examination at study entry |                             |                   |                               |                   |                          |                   |
| - Dilatation (cm)                | 1.0 (1.0–2.0)               | 1.5 (1.0–2.0)     | 1.0 (1.0–2.0)                 | 1.0 (1.0–2.0)     | 1.5 (1.0–2.0)            | 1.5 (1.0–2.0)     |
| - Effacement (%)                 | 75 (50–100)                 | 75 (50–100)       | 75 (50–100)                   | 75 (50–100)       | 75 (50–75)               | 75 (50–75)        |

Data are median (IQR), n(%) or n/N (%). BMI Body mass index

* nifedipine n = 273 (198 + 75), atosiban n = 277 (207 + 70)
* nifedipine n = 323 (248 + 75), atosiban n = 326 (256 + 70)
* nifedipine n = 187 (112 + 75), atosiban n = 191 (121 + 70)
* nifedipine n = 162 (87 + 75), atosiban n = 170 (100 + 70)
### Table 2 Primary outcome and composites

| Characteristics                  | IPDMA                        | Nifedipine (n = 392) | Atosiban (n = 380) | OR or MD (95% CI) | Van Vliet                      | Nifedipine (n = 294) | Atosiban (n = 289) | OR or MD (95% CI) | Salim                       | Nifedipine (n = 98) | Atosiban (n = 91) | OR or MD (95% CI) |
|----------------------------------|------------------------------|----------------------|--------------------|-------------------|------------------------------|----------------------|--------------------|-------------------|-----------------------------|----------------------|----------------------|-------------------|
| Composite outcome<sup>a</sup>    | 58/364 (16)                  | 69/359 (19)          | 0.76 (0.47–1.2),  p = 0.27 | 51/267 (19)       | 60/268 (22)                   | 0.77 (0.12–5.0),  p = 0.79 | 7/97 (7.2)         | 9 (9.9)          | 0.63 (0.017–24),  p = 0.81 |
| Perinatal death                  | 14 (3.6)                     | 7 (1.8)              | 2.01 (0.80–5.1),  p = 0.14 | 14 (4.8)          | 7 (2.4)                       | 2.01 (0.80–5.1),  p = 0.14 | 0                  | 0                | –                           |
| Intraventricular hemorrhage      | 6/391 (1.5)                  | 3/379 (0.8)          | 1.95 (0.49–7.9),  p = 0.35 | 5 (1.7)           | 2/288 (0.70)                  | 2.47 (0.48–13),  p = 0.28 | 1/97 (1.0)         | 1 (1.1)          | 0.94 (0.058–15),  p = 0.96 |
| Necrotizing enterocolitis        | 7 (1.8)                      | 8/379 (2.1)          | 0.84 (0.30–2.4),  p = 0.74 | 7 (2.4)           | 4/288 (1.4)                   | 1.73 (0.50–6.0),  p = 0.39 | 0                  | 4 (4.4)          | –                           |
| Respiratory distress syndrome    | 37 (10)                      | 44 (12)              | 0.76 (0.090–6.4),  p = 0.80 | 32/267 (12)       | 41/267 (15)                   | 0.72 (0.070–7.4),  p = 0.79 | 5 (5.1)           | 3 (3.3)          | 1.39 (0.008–242),  p = 0.90 |
| Culture-proven sepsis            | 27 (6.9)                     | 27/379 (7.1)         | 0.87 (0.058–13),  p = 0.92 | 24 (8.2)          | 25/288 (8.7)                  | 0.84 (0.051–14),  p = 0.91 | 3 (3.1)           | 2 (2.2)          | 1.34 (0.00–1566),  p = 0.95 |

Data are median (IQR) or n/N (%). OR: odds ratio. MD: median difference

<sup>a</sup> includes perinatal death, IVH, NEC, RDS requiring surfactant and culture-proven sepsis

### Table 3 Neonatal and maternal secondary outcomes

| Characteristics                  | IPDMA                        | Nifedipine (n = 392) | Atosiban (n = 380) | HR or OR (95% CI) or χ² test | Van Vliet                      | Nifedipine (n = 294) | Atosiban (n = 289) | OR or MD (95% CI) | Salim                       | Nifedipine (n = 98) | Atosiban (n = 91) | OR or MD (95% CI) |
|----------------------------------|------------------------------|----------------------|--------------------|-----------------------------|------------------------------|----------------------|--------------------|-------------------|-----------------------------|----------------------|----------------------|-------------------|
| GA at delivery (weeks)<sup>a</sup> | 33 ± 6 (31 ± 1–37 + 2)       | 33 ± 0 (30 ± 3–36 + 3) | HR 0.80 (0.67–0.95),  p = 0.013 | 33 + 1 (30 + 4–37 + 0)       | 32 ± 3 (30 + 1–36 + 0) | HR 0.85 (0.70–1.03),  p = 0.10 | 36 + 4 (34 + 0–38 + 1) | 34 + 5 (33 + 0–38 + 0) | HR 0.60 (0.40–0.90),  p = 0.014 |
| Time to delivery (days)<sup>a</sup> | 18 (2–44)                    | 10 (2–42)            | HR 0.83 (0.69–0.99),  p = 0.038 | 7.5 (1.0–39.0)              | 4.0 (1.0–38.5)            | HR 0.88 (0.72–1.06),  p = 0.18 | 35.0 (23.0–49.5)       | 32.0 (15.0–50.0) | HR 0.61 (0.40–0.94),  p = 0.024 |
| Successful 48 hours of tocolysis | 247 (77)                     | 243 (76)             | OR 1.06 (0.73–1.53),  p = 0.77  | 177 (72)                     | 181 (72)                   | OR 0.99 (0.67–1.47)        | 70 (93)           | 62 (89)         | OR 1.81 (0.56–5.81) |

Data are median (IQR) or n/N (%). OR: Odds ratio, MD: Median difference

<sup>a</sup> censored at 37 + 0 weeks

<sup>b</sup> includes perinatal death, sepsis, IVH, NEC, RDS
The Kaplan–Meier curve for prolongation of pregnancy (Fig. 1) demonstrated a log-rank test with $P = 0.026$, indicating that nifedipine results in longer prolongation of pregnancy, regardless of the gestational age at study inclusion. This corresponds with a longer time to delivery of 18 days with nifedipine versus 10 days with atosiban ($HR\ 0.83, \ 95\%\ CI\ 0.69–0.99, \ P = 0.038$) and a higher gestational age at delivery of $33^{+6}$ week with nifedipine versus $33^{+10}$ weeks with atosiban ($HR\ 0.80, \ 95\%\ CI\ 0.67–0.95, \ P = 0.013$). None of the other secondary outcomes, such as IVH, NEC, RDS or sepsis occurred more frequently in one of the treatment groups.

**Subgroup analysis**

Subgroup analyses of the effect of treatment allocation are summarized in supplementary Appendix S2. Regarding the planned subgroup analysis with stratification by cervical length less than 15 mm, the trial of Salim et al. did not register cervical length data. Otherwise, the data available from the trials were eligible for comparison.

Nifedipine was associated with a statistically significant increase in gestational age at delivery and time to delivery in women with intact membranes ($OR\ 0.70\ (95\%\ CI\ 0.56–0.87)\ and\ 0.71\ (95\%\ CI\ 0.57–0.89),\ respectively$). Successful tocolysis for at least 48 hours was achieved with nifedipine more often in subgroup of more than 2 cm dilatation ($OR\ 2.2\ (95\%\ CI\ 1.07–4.76)$). Moreover, for women with a history of preterm birth, nifedipine-exposed children less often faced the composite adverse outcome ($OR\ 0.18\ (95\%\ CI\ 0.034–0.92)$). This effect was not visible in women with no history of preterm birth or in women with or without a history of term birth.

The composite adverse neonatal outcome did not differ significantly when comparing women with or without ruptured membranes, with gestational age at study entry less or above 30 weeks, with dilatation at study entry less or above 2 cm, when comparing singleton and multiple pregnancies or nulliparous and multiparous women. Lastly, no significant difference in composite adverse outcome could be related to neonatal sex.

**Sensitivity analysis (synthesis of four studies, using individual data when available)**

We performed a sensitivity analysis by pooling the reported data of all four studies that directly compared neonatal outcomes for tocolysis using nifedipine and atosiban in an aggregate meta-analysis.

There was no difference in prolongation of pregnancy for 48 hours ($OR\ 1.0,\ 95\%\ CI\ 0.73–1.4$) or 7 days ($OR\ 1.3,\ 95\%\ CI\ 0.85–5.8$) between nifedipine and atosiban.
However, when looking at mortality, there is a non-significant higher neonatal mortality in the nifedipine-exposed group (OR 1.4, 95% CI 0.60–3.4). These results are visualized in Appendix S3.

Risk of bias assessment
The risk of bias of the included studies was assessed independently by two reviewers (TN and CR) using the Cochrane Collaboration’s risk-of-bias tool, as visualized in Table 4 [10]. This includes the assessment of adequate sequence generation, allocation concealment, blinding of participants and personnel, and blinding for outcome measures, incomplete outcome data, and other sources of bias. Both of the studies were considered to be at low risk of bias arising from the randomization process, bias due to missing outcome data and bias in measurement of the outcome. Selective reporting of outcome was not considered as a relevant bias in this IPDMA, as original databases are used instead of reported outcomes. For both studies the assessors reported some concerns regarding bias due to deviations from intended intervention. The leading cause for this, is the tool’s subheading “were participants aware of their assigned intervention during the trial?” Due to the obligatory routes of administration of the used tocolytics, complete blinding of the group allocation was not possible: nifedipine is given orally, while atosiban is solely administered intravenously. This leads the overall risk of bias score for both studies to be “some concerns”.

Discussion
In this IPDMA encompassing 650 women, no clear superior tocolytic could be determined. Prolongation of pregnancy was longer with nifedipine, independent of gestational age. This was also reflected in a longer time to delivery and higher gestational age at delivery. However, the prolonged pregnancy did not reduce the rate of adverse neonatal outcome, apart from a lower rate of NICU admission with nifedipine. A sensitivity analysis including all RCT’s that compared nifedipine and atosiban did not show a prolongation of pregnancy for 48 hours or 7 days. We found a non-significant higher number of neonatal deaths in the nifedipine group. These findings should be taken into account when considering atosiban or nifedipine in women presenting with a threatened preterm birth.

Strengths and limitations
This study has several strengths: by performing an IPDMA, we could investigate a relatively large population and this allowed for more power in subgroup analyses. Second, by analyzing individual participant data, we could overcome the problem of selective reporting. This also resulted in some outcomes in this IPDMA differing from the reported outcomes in the original articles. For example, in our analyses we only considered a neonate to have RDS when the clinical condition was severe enough to warrant administration of surfactant, while this differed from one of the included studies. Another explanation is the exclusion of women who did not meet the criteria defined in our study protocol. This was the case for 6 women in the database of Van Vliet et al., leading to exclusion of two cases of perinatal mortality.

Lastly, in rare cases the new analyses for this IPDMA resulted in minor differences from the published data. It should be noted that the included studies levelled out some of their reported outcomes such as neonatal morbidities which in the study by Van Vliet et al. were more frequent with atosiban and in Salim et al. occurred more often with nifedipine.

Our study also has some limitations. As not all of the planned outcome measures were available, it was not feasible to perform an IPDMA with our initial planned data points. Primarily we chose to implement the outcomes as defined in the Core Outcome Set published in 2016 [15]. Since Salim’s study was published before this in 2012, not all of the outcomes were reported. On the other hand, maternal side effects were reported in different items e.g., headache, palpitations, nausea, pruritus, but were not accurately recorded in Van Vliet et al. We had to redefine one of our IPDMA outcome measures accordingly and sought to find adequate proxies for initial outcome measures as planned in protocol. As measure for airway and breathing problems, we planned to include BPD.

Table 4  Risk of bias in included studies

| Study          | Random sequence generation | Deviations from intended intervention | Missing outcome data | Measurement of the outcome | Selection of reported results | Overall |
|---------------|----------------------------|-------------------------------------|---------------------|---------------------------|-------------------------------|---------|
| Salim 2012 [12] | +                         | ?                                   | +                  | +                         | +                             | ?       |
| Van Vliet 2016 [11] | +                         | ?                                   | +                  | +                         | +                             | ?       |

Risk of bias judgement:  + Low risk of bias, ? Some concerns, - High risk of bias
This was not reported in the study of Salim, but RDS was recorded in both databases, so we chose to report this instead, preventing excluding outcomes on breathing problems entirely. On the other hand, we could include additional outcomes such as NICU admission, ventilation support, total days in hospital, total days in hospital until corrected age 3 months, apnea and birthweight, that were recorded in both databases.

Unfortunately, we could not retrieve the entire outcome databases of two other studies, and it was thus not possible to perform an IPDMA on all the RCT’s comparing nifedipine and atosiban. In addition, these studies did not assess all outcomes predefined in the protocol.

One point deserving attention, is a possible difference in risk profile between women in the two studies. Women included in Van Vliet et al. are slightly older, have a higher BMI and lower gestational age at randomization, compared to Salim et al. Moreover, this trial included women with ruptured membranes, which in itself drastically increases the risk to deliver. Given that we wanted to include all available evidence in a field of tocolytics where high-quality trials are already scarce, also women with PPROM were included. Many guidelines from societies across the world advocate administering tocolytics, also in case of ruptured membranes in absence of clinical infection. Because there is a chance that the outcome may be different between women with and without ruptured membranes, we performed a subgroup analysis for women with ruptured membranes versus intact membranes. This yielded no different outcome between these groups.

Women with PPROM in the Apostel III RCT were treated according to the national guideline “Threatened preterm birth” by the NVOG (Dutch Society of Obstetrics and Gynaecology) [16]. This guideline indicates administration of corticosteroids and tocolytics for 48 hours for women in threatened preterm birth between 24 and 34 weeks of gestation. Afterwards, if no signs of infection are present, expectative management is advocated. Preventive treatment with antibiotics in women with PPROM was not routinely initiated, unless a patient had been diagnosed as a GBS carrier or if there were clinical signs of intra-uterine infection. In this case, treatment was initiated according to local protocol. From the women in the latter group on the other hand, more carried a twin pregnancy and more women experienced previous preterm birth. Of course, the question remains whether this possible heterogeneity should be translated in an implication for treatment choice. Since we compared differences in outcomes between nifedipine and atosiban and those groups are evenly represented in both databases, we believe the combined database offers a picture representative for patients in daily practice.

**Interpretation and clinical implications**

The apparent superiority for nifedipine regarding prolongation of pregnancy that was described in the trial of Salim et al. and that was visualized in the survival curve of Van Vliet et al., is a promising sign that was captured in Fig. 1. However, this advantage did not lead to a better neonatal outcome. Neither could a difference be demonstrated by pooling this data with all other available evidence, as shown in the sensitivity analysis. The lower rate of NICU admission we found in the nifedipine-exposed group, may be attributed to the higher gestational age at delivery. However, as noted, this did not lead to the generally accepted consequence that this also improves neonatal outcome as this would have been reflected in reduction in perinatal mortality, RDS, IVH, PVL, NEC or sepsis.

Another possible explanation can be derived from a follow-up study, where mortality until the age of 2.5–5.5 years was higher in the nifedipine group, while for the remaining group healthy survival occurred more often than in atosiban-exposed children [17].

Based on this finding, the hypothesis was raised that there seems to be a trade-off between these two outcomes, possibly suggesting that the non-significantly higher mortality with nifedipine, also leaves the surviving children on average less impacted by preterm birth; the same mechanism could contribute to the demonstrated lower rate of NICU admittance. However, thorough research with a large number of participants should be conducted to answer this question.

Summarized, a slightly longer delay of delivery with nifedipine did not reflect in better neonatal outcomes. The non-significant higher mortality rate in the nifedipine group remains a matter of concern. While nifedipine is a more potent tocolytic agent, in certain subgroups of patients with threatened preterm birth, prolongation of pregnancy may not be beneficial for the infant. Another explanation is that the surviving part of neonates exposed to nifedipine were relatively less impaired than their counterparts in the atosiban group. Although changes in uterine blood flow, occurrence of fetal acidemia and reduced fetal movements have been demonstrated in animals, neither of these effects was observed in human studies [18–25].

The field of tocolytics, although studied for a long time, remains to be surrounded by many questions. In this respect, it is disappointing that only four studies reported on tocolysis with nifedipine and atosiban in threatened preterm birth. Since we believe that individual participant data is the preferred source for performing a meta-analysis, we stuck to the studies that provided these, hence reducing the number of serviceable studies to two.
Without question, it would be desirable to collect more data in order to draw more definitive conclusions. The paucity of literature describing (long-term) neonatal outcomes, raises a problem for clinicians considering a tocolytic for their patients. The optimal drug of choice should be not only effective in delaying delivery, but should improve neonatal outcome, as compared to placebo or no treatment. In addition, these drugs should have a favorable side effect profile on both maternal and fetal side. Also, long term follow-up of these studies should be performed in order to assess the effect on the child later in life. Placebo-controlled trials, especially on the currently used drugs, are rare, and not of sufficient size to draw conclusions. Therefore, we urge clinicians to re-evaluate the policy regarding the use of tocolysis. It is our opinion that tocolytic drugs should only be used within the setting of a placebo-controlled trial, with neonatal outcome as a primary outcome, and assessing long term follow-up. The WHO guideline on preterm birth is in agreement with this statement and does not advice to use tocolytics for the purpose of improving neonatal outcomes [26].

**Conclusion**

Nifedipine and atosiban are equally effective in the treatment of threatened preterm birth. Nifedipine results in a lower rate of NICU admission and longer duration of pregnancy, however did not result in an improved neonatal outcome. In women with a history of preterm birth, the composite outcome occurred less frequently in nifedipine-exposed children. There is a non-significant higher mortality after administering nifedipine which warrants further investigation of the use of nifedipine as a tocolytic drug.

**Abbreviations**

IPDIMA: Individual participant data meta-analysis; PPROM: Preterm prelabor rupture of membranes.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s12884-022-04854-1.

**Acknowledgements**

The authors express their gratitude to the hundreds of women with threatened preterm birth who have consented to participate in randomized trials comparing nifedipine and atosiban and to the dozens of co-investigators, collaborators, and research personnel who conducted the original trials.

**Authors’ contributions**

MO, BWM, TN and TvW were involved in the concept and design of the study, TN, RS, MK and WAO were involved in the design, performance and reporting of one of the trials included in the meta-analysis and in making their individual patient data available for meta-analysis. TN, BWM and MO wrote the initial protocol, which was later modified by TvW. The draft of the manuscript was written by TvW, in close correspondence with TN, CK, EP, BWM, MO and CR. CK performed the statistical analyses in collaboration with TvW, BWM and MO. TvW, TN, CK, RS, MK, WAO, EP, BWM, MO and CR participated in face-to-face meetings, phone calls, and/or e-mail exchanges at all phases of the study, were involved in making critical revisions to the protocol and to the manuscript, and approved the final version. Study supervision: EP, BWM, MO and CR.

**Funding**

This study received no external funding.

**Availability of data and materials**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

**Declarations**

**Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

**Competing interests**

Ben W. Mol is supported by a NHMRC Investigator grant (GNT1176437) and reports consultancy for Merck. Eva Pajkrt reports a grant from ZonMW (PPROMEXIL follow-up study). The other authors declare that they have no competing interests.

**Author details**

1Department of Obstetrics, Amsterdam UMC location University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands. 2Amsterdam Reproduction and Development Research Institute, Amsterdam, The Netherlands. 3Department of Obstetrics and Gynecology, Medisch Centrum Haaglanden, The Hague, Netherlands. 4Department of Obstetrics and Gynecology, Emek Medical Center, Afula, Israel. 5Department of Obstetrics & Gynecology, Akbarabadi Teaching Hospital, Tehran, Iran. 6Department of Obstetrics and Gynecology, Medical City Teaching Hospital, Baghdad, Iraq. 7Department of Obstetrics and Gynaecology, Monash University, Clayton, Victoria, Australia. 8Department of Obstetrics, Amsterdam UMC, location Vrije Universiteit Amsterdam, Boelelaan, 1117 Amsterdam, The Netherlands. 9Department of Obstetrics and Gynaecology, Amsterdam Reproduction and Development Research Institute, Amsterdam UMC, Location AMC, H4-275, PO Box 22660, Amsterdam 1100, DD, The Netherlands.

**Received:** 28 February 2022   **Accepted:** 29 April 2022

**Published online:** 15 July 2022

**References**

1. Lawn JE, Cousens S, Zupan J. 4 million neonatal deaths: when? Where? Why? Lancet. 2005;365(9462):891–900.
2. Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller A-BB, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–72.
3. Organization WH. WHO recommendations on interventions to improve preterm birth outcomes: World Health Organization. p. 98.
4. Keirse MJNC. The history of tocolysis. BJOG an Int. J Obstet Gynaecol. 2003;110(s20):94–7.
5. Moher D, Liberati A, Tetzlaff J, Altman DG, Group TP. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA statement. Plos Med. 2009;6(7):e1000097.
6. Twisk JWR. Software for multilevel analysis. Applied Multilevel Analysis. Cambridge: Cambridge University Press, 2014. p. 769–76.
7. Gates S, Brocklehurst P. How should randomised trials including multiple pregnancies be analysed? BJOG An Int J Obstet Gynaecol. 2004;111(3):213–9.

8. Geraci M. Linear Quantile Mixed Models: The lqmm Package for Laplace Quantile Regression. J Stat Software. 2014;57:1–29. https://doi.org/10.18637/jss.v057.i13.

9. Higgins JPT. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–60.

10. Higgins JPT, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343(Oct 18 2):d5928.

11. Van Vliet EOG, Nijman TAJ, Schuit E, Heida KY, Opmeer BC, Kok M, et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet. 2016;387(10033):2117–24.

12. Salim R, Garmi G, Nachum Z, Zafran N, Baram S, Shalev E. Nifedipine compared with atosiban for treating preterm labor: a randomized controlled trial. Obstet Gynecol. 2012;119(1):123–31.

13. Al-Omari WR, Al-Shammah HB, Al-Tikriti EM, Ahmed KW. Atosiban and nifedipine in acute tocolysis: a comparative study. Eur J Obstet Gynecol Reprod Biol. 2006;128(1–2):129–34.

14. Kashanian M, Alkarian AR, Solfanzadeh M. Atosiban and nifedipine for the treatment of preterm labor. Int J Gynecol Obstet. 2005;91(1):10–4.

15. van’t Hooft J, JM N D, Daly M, Williamson PR, Meher S, Thom E, et al. A core outcome set for evaluation of interventions to prevent preterm birth. Obstet Gynecol. 2016;127(1):49–58.

16. Nederlandse Vereniging voor Obstetrie en Gynaecologie. Richtlijn dreigende vroegegeboorte. https://richtlijnendatabase.nl/richtlijn/dreigende_vroegegeboorte/tocolyse_bij_dreigende_vroegegeboorte.html.

17. Winden T, Klumper J, Kleinrouwele CE, Tichelaar MA, Naaaktgeboren CAC, Nijman TAT, et al. Effects of tocolysis with nifedipine or atosiban on child outcome: follow up of the APOSTEL III trial. BJOG. 2020;127(9):1129–37.

18. Furusashi N, Tsujie M, Kimura H, Yajima A. Effects of nifedipine on normotensive rat placental blood flow, placental weight and fetal weight. Gynecol Obstet Invest. 1991;32(1):1–3.

19. Lirette M, Holbrook RH, Katz M. Cardiovascular and uterine blood flow changes during nicardipine hcl tocolysis in the rabbit. Obstet Gynecol. 1987;69(1):79–82.

20. Harake B, Gilbert RD, Ashwal S, Power GG. Nifedipine: effects on fetal and maternal hemodynamics in pregnant sheep. Am J Obstet Gynecol. 1987;157(4):1003–8.

21. Blea CW, Bamard JM, Magness RR, Phermetton TM, Hendricks SK. Effect of nifedipine on fetal and maternal hemodynamics and blood gases in the pregnant ewe. Am J Obstet Gynecol. 1997;176(4):922–30.

22. Mari G, Kirshon B, Moise KJ, Lee W, Cotton DB. Doppler assessment of the fetal and uteroplacental circulation during nifedipine therapy for preterm labor. Am J Obstet Gynecol. 1989;161(6 PART 1):1514–8.

23. Pirhonen JP, Erkkola RU, Ekblad UU, Nyman L. Single dose of nifedipine in normotensive pregnancy: Nifedipine concentrations hemodynamic responses, and uterine and fetal flow velocity waveforms. Obstet Gynecol. 1990;76(5 I):807–11.

24. Guclu S, Saygili U, Dogan E, Demir N, Baschat AA. The short-term effect of nifedipine tocolysis on placental, fetal cerebral and atrioventricular Doppler waveforms. Ultrasound Obstet Gynecol. 2004;24(7):761–5.

25. De Heus R, Mulder EJH, Derks JB, Visser GHA. The effects of the tocolytics atosiban and nifedipine on fetal movements, heart rate and blood flow. J Matern Neonatal Med. 2009;22(6):485–90.

26. Vogel JP, Oladapo OT, Manu A, Gulmezoglu AM, Bahl R. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Heal. 2015;3(10):e589–90.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.